NGM120
Phase 2Biologic
NGM120 is one of 48 biologic programs targeting Colorectal Cancer. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
254 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 3
Fudr
PfizerPhase 3
Tecentriq
RochePhase 3
Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Decadron
AAspen Global Incorporated
Phase 3
5-Fu
TToray Industries, Inc
Phase 3
PD-1 Monoclonal Antibody
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
BL-M07D1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
Calcium Levofolinate
FFujian Cancer Hospital
Phase 3
Trodelvy
GileadPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Colorectal Cancer1 trial
Pancreatic Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NGM120. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- NNGM Biopharmaceuticals, Inc